Alpelisib (Piqray) — targeted treatment for breast cancer with a PIK3CA change

What alpelisib is in simple patient language

Piqray — brand name. Alpelisib — the drug name in medical records. A targeted cancer tablet. Not a general breast cancer drug.

Why it comes up: the tumor still has an ER or PR side, HER2 is not the main target, and testing found a PIK3CA change. Without that piece, the reason for this drug is weak.

Often it is discussed together with endocrine treatment, for example fulvestrant. The mutation matters. So does the story before it: prior pills, CDK4/6 treatment, scans, sugar levels, skin history, bowel problems, weight, and daily strength.

Tablet form can make treatment look simple. Here it is not simple. Sugar, rash, diarrhea, appetite, labs, and regular medicines all have to be part of the plan from the start.

How alpelisib works

Some breast cancer cells use the PI3K route as one of their growth routes. When PIK3CA is changed, that route can become too loud.

Alpelisib tries to quiet that route. In plain words, it makes one growth message less useful for the tumor cell.

That is why the drug often sits next to endocrine treatment. One part works on the hormone side. The other part works on the PIK3CA signal.

The mechanism is only the start of the conversation. The doctor still has to ask: can this patient get through the treatment safely? Sugar and skin often decide that question.

Which diseases alpelisib may be used for

Alpelisib is mainly discussed in breast cancer with the right biology. Not every breast cancer. Not every report with a mutation.

• breast cancer where ER and/or PR are part of the tumor picture
• HER2 is not the leading treatment target
• PIK3CA change is confirmed in tumor tissue or tumor DNA from blood
• endocrine treatment no longer holds the disease well enough
• the doctor is weighing a targeted endocrine plan against another systemic step

If the same mutation appears in another tumor type, that alone does not make Piqray the answer. Diagnosis, line of treatment, pace of disease, and patient condition still matter.

When alpelisib can be especially relevant

The discussion usually starts after molecular testing. PIK3CA appears in the report, and the doctor asks whether this signal is one reason hormone control became weaker.

It can make sense when the tumor still behaves like hormone-sensitive disease, the situation is not an immediate crisis, and previous endocrine treatment has lost its hold.

Past CDK4/6 treatment matters here. So do metastases, scan trend, pain, appetite, sugar history, rash history, diarrhea, and whether the patient can stay on daily tablets without being pulled down by side effects.

Sometimes the goal is to stay on a targeted endocrine path a little longer. Sometimes high sugar, rash, diarrhea, or frailty makes another route safer.

What needs to be checked before treatment

One test result is not enough. The doctor needs the disease picture and the patient picture.

• PIK3CA report, with the material used for the test
• ER, PR, and HER2 status from the most useful recent data
• full prior treatment list and how each step worked
• fresh scans and the current pace of the disease
• morning glucose value, HbA1c, and any history of sugar problems
• diabetes, prediabetes, weight, and steroid use
• CBC, liver and kidney values, electrolytes
• prior rash, diarrhea, mouth sores, infections, breathing trouble, severe weakness
• all regular medicines, supplements, and pills taken only when needed

Sugar is not a side detail with this drug. If it is already unstable, the plan may need an endocrinologist, home checks, diet changes, or a delay before the first tablet.

How treatment with alpelisib goes

Alpelisib is taken by mouth on the oncology plan. Fulvestrant, when used, has its own visit schedule. Do not mix the two schedules in your head.

The first weeks matter a lot. Sugar can rise fast. Skin can react early. Diarrhea can pull the patient down before the next planned visit.

During treatment, doctors usually follow:

• home sugar readings, thirst, and urination
• rash, itching, swelling, mouth sores, and skin pain
• stool pattern, belly pain, nausea, appetite, and weight
• CBC, liver and kidney values, electrolytes
• temperature, infection signs, weakness, and ability to drink
• planned scans or markers used in this case

A dose change or a short pause is not automatically a failure. Sometimes it is how the team keeps the treatment possible. The patient should not fix the dose alone.

Possible side effects

Alpelisib has a side effect pattern patients should hear about before the first tablet. The main words are sugar, skin, and gut.

• higher sugar, strong thirst, dry mouth, frequent urination
• rash, itching, red skin, sometimes a stronger skin reaction
• diarrhea, cramps, nausea, lower appetite
• tiredness, weight loss, low energy
• mouth soreness or small ulcers
• changes in blood work or blood chemistry
• less often, bowel or lung inflammation complaints

Small symptoms are worth reporting early. It is much easier to adjust sugar, skin treatment, fluids, or the dose before the patient is dehydrated or very weak.

When to contact a doctor urgently

Do not wait for a planned visit if any of these appear:

• heavy thirst, frequent urination, confusion, sharp weakness, or acetone smell on the breath
• rash spreading quickly, blisters, mouth or eye soreness, face swelling, or trouble breathing
• watery stool many times a day, blood in stool, or strong belly pain
• vomiting, inability to drink, dry mouth, dizziness
• fever, chills, clear infection signs, or sudden loss of strength
• new breathlessness, new cough, or chest discomfort
• fast worsening after the tablets were started

These symptoms do not always mean the drug is stopped forever. They do mean the situation needs medical judgment quickly: labs, fluids, sugar correction, a pause, or in-person care may be needed.

Why alpelisib is not right for everyone

Alpelisib is not a universal breast cancer option. The biology has to fit first. If the PIK3CA result is missing or unclear, the doctor usually has to look elsewhere.

Safety can block the route too. Poorly controlled diabetes, severe weakness, active infection, bad diarrhea, or a strong skin risk can make the treatment too heavy for that patient.

Disease pace also matters. If the cancer is threatening an organ quickly, the doctor may choose a faster or different kind of control. Piqray gets judged inside the whole plan, not as a name on its own.

Can alpelisib be combined with other methods

Usually the main partner is endocrine treatment. The exact pair depends on prior therapy, tumor behavior, sugar risk, skin risk, gut tolerance, and general condition.

Other support may sit around the cancer plan: radiation to a painful bone spot, bone-strengthening treatment, pain control, nutrition help, or endocrine help for sugar. Those steps do not replace the anti-cancer plan. They help the patient get through it.

Adding more cancer drugs just to make the plan look stronger is not the point. More drugs can also mean more toxicity and more conflicts.

What no quick response to treatment can mean

Many patients wait for a fast sign: less pain, a lower marker, better scans. Alpelisib does not always answer that quickly.

Sometimes the first useful sign is not shrinkage. It is that the disease stops moving so fast, symptoms stay calmer, and labs allow treatment to continue.

One marker is not the whole story. The doctor reads symptoms, scans, tumor markers, new complaints, sugar problems, rash, diarrhea, and how the patient feels overall.

The timing of the first control should be clear before starting. Without that, it is easy to stop too early or stay too long with a plan that is not working.

Oncology consultation in Israel about alpelisib

At Tel Aviv Medical Clinic, patients can discuss whether alpelisib has a real place in their breast cancer plan. This is not remote prescribing and not a promise of response.

The consultation is useful when Piqray was offered, but the patient still needs to understand the mutation, the sugar risk, the skin risk, the previous treatments, and the alternatives.

A consultation may help to:

• review the PIK3CA report and whether the data are enough
• look at ER, PR, HER2, scans, and treatment history together
• think through sugar control before the first dose
• prepare questions about rash, diarrhea, dose changes, and follow-up
• compare Piqray with another systemic option
• organize the documents for the treating oncologist

We do not replace the treating doctor. We help the patient and family understand the medical logic and prepare for the next discussion.

Frequently asked questions — answered by Dr. Stefanska

1. Is Piqray for every breast cancer patient?

No. I would not choose it from the words “breast cancer” alone. I first look for the right pattern: ER or PR is present, HER2 is not the main target, and PIK3CA is confirmed. Then I look at sugar, scans, prior treatment, and how strong the patient is now.

2. Why does the PIK3CA test matter so much?

Because that is the reason this drug is even on the table. I do not want only a short phrase in a discharge letter. I want the real report: what was tested, when, from tissue or blood, and exactly what was found. Sometimes that changes the whole talk.

3. If sugar is already high, is alpelisib impossible?

Not always. But high sugar makes the start more serious. I want the morning glucose number, HbA1c, diabetes history, medicines, weight, and a home plan. If sugar is poorly controlled, we may need to fix that first. Starting blindly is not safe.

4. What if a rash appears?

Tell the treating team early. A small rash is not always a disaster, but it should not be hidden. If it spreads fast, blisters appear, the mouth or eyes hurt, the face swells, or breathing becomes hard, that is urgent. The doctor decides whether support, a pause, or an exam is needed.

5. What should the patient do with diarrhea?

Do not wait several days. Count how often it happens. Notice whether the patient can drink, whether there is fever, blood, dizziness, or belly pain. Sometimes early support is enough. Sometimes the drug has to pause for safety.

6. How do we know if the treatment is working?

Not from one day and not from one marker. I look at scans, symptoms, tumor markers if they are used, side effects, and the pace before treatment. Sometimes stable disease is already an important first result. The first control date should be agreed in advance.

7. What documents should be prepared for a consultation?

Bring the oncology summary, pathology, ER, PR, HER2, the PIK3CA report, previous treatment list with dates, recent CT, PET-CT, or MRI, blood tests, sugar data, and the current medicine list. A short timeline helps a lot: diagnosis, treatments, response, progression, and why Piqray is being discussed now.

Important information

General medical information only. Not a treatment recommendation. Alpelisib can be discussed only after the diagnosis, molecular data, prior treatment, labs, sugar status, and overall condition are reviewed.

Do not start, stop, or change the dose on your own. High sugar, strong rash, diarrhea, breathlessness, fever, or sudden worsening should not wait for a routine visit.

Contacts

To arrange a consultation about alpelisib:

📞 +972-73-374-6844

📧 [email protected]

💬 WhatsApp: +972-52-337-3108